Ancora Advisors’s BridgeBio Pharma BBIO Stock Holding History

Ancora Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100	Closed	-$7.43K	–	2026
2026 Q1	$7.43K	Buy	+100	New	+$7.25K	﹤0.01%	1859

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Ancora Advisors's BBIO Position: Q2 2026 in Review

Ancora Advisors sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 100 shares — an estimated $7.43K sold.

Ancora Advisors first reported a position in BBIO in Q1 2026 and held it in 1 quarter. The position peaked at $7.43K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Ancora Advisors reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Ancora Advisors sold 100 BridgeBio Pharma shares in Q2 2026, an estimated $7.43K.
Ancora Advisors first reported a position in BridgeBio Pharma in Q1 2026 and held it in 1 quarter.
Ancora Advisors's BridgeBio Pharma position peaked at $7.43K in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.